Bulletin
Investor Alert

Roche Holding AG Part. Cert.

OTC: RHHVF

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
Roche Holding AG Part. Cert.

Market closed

 --Quotes are delayed by 20 min

Feb 8, 2023, 3:49 p.m.

RHHVF
/zigman2/quotes/206948568/delayed

$

306.51

Change

-1.26 -0.41%

Volume

Volume 2,104

Quotes are delayed by 20 min

/zigman2/quotes/206948568/delayed

Previous close

$ 307.77

$ 306.51

Change

-1.26 -0.41%

Day low

Day high

$306.51

$314.99

Open

52 week low

52 week high

$298.00

$430.00

Open

Company Description

Roche Holding AG operates as a research healthcare company. It operates through the following divisions: Pharmaceuticals and Diagnostics. The Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four busin...

Roche Holding AG operates as a research healthcare company. It operates through the following divisions: Pharmaceuticals and Diagnostics. The Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized and point of care solutions, molecular diagnostics, tissue diagnostics and diabetes care. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Valuation

P/E Current

18.32

P/E Ratio (with extraordinary items)

18.31

P/E Ratio (without extraordinary items)

14.31

Enterprise Value to EBITDA

11.10

Enterprise Value to Sales

3.86

Efficiency

Liquidity

Cash Ratio

0.36

Profitability

Net Margin

21.38

Capital Structure

Officers and Executives

Name Age Officer Since Title
Dr. Severin Schwan 54 2008 Chief Executive Officer
Dr. Alan Hippe 54 2011 Chief Financial Officer
Dr. Levi A. Garraway - - Chief Medical Officer
Dr. Gallia G. Levy - - Associate Group Medical Director-Hematology
Ms. Pascale Schmidt 47 2020 Chief Compliance Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
10/19/2022 DIRECTOR Swiss Non EXECUTIVE
610   Acquisition at $328.68 per share. 200,493
05/13/2022 Executive Officer Swiss
1   Acquisition at $319 per share. 319
05/13/2022 Executive Officer Swiss
1   Acquisition at $319 per share. 319
05/13/2022 Executive Officer Swiss
1   Acquisition at $319 per share. 319
05/13/2022 Executive Officer Swiss
1   Acquisition at $319 per share. 319
05/11/2022 Executive Officer Swiss
1,500   Acquisition at $326.78 per share. 490,162
03/30/2022 Executive Officer Swiss
1,624   Disposition at $373.14 per share. 605,971
03/30/2022 Executive Officer Swiss
1,624   Disposition at $373.14 per share. 605,971
12/16/2021 Executive Officer Swiss
19,920   Disposition at $379.95 per share. 7,568,627
12/16/2021 Executive Officer Swiss
19,920   Disposition at $379.95 per share. 7,568,627
12/16/2021 Executive Officer Swiss
19,920   Derivative/Non-derivative trans. at $379.95 per share. 7,568,627
12/16/2021 Executive Officer Swiss
19,920   Derivative/Non-derivative trans. at $379.95 per share. 7,568,627
08/12/2021 Executive Officer Swiss
3,163   Disposition at $368.23 per share. 1,164,698
08/12/2021 Executive Officer Swiss
3,163   Disposition at $368.23 per share. 1,164,698
08/09/2021 Executive Officer Swiss
8,788   Acquisition at $362.2 per share. 3,183,013
08/09/2021 Executive Officer Swiss
8,788   Acquisition at $362.2 per share. 3,183,013
08/09/2021 DIRECTOR Swiss Non EXECUTIVE
271   Acquisition at $394.4 per share. 106,881
08/09/2021 DIRECTOR Swiss Non EXECUTIVE
271   Acquisition at $394.4 per share. 106,881
07/30/2021 Executive Officer Swiss
4,317   Disposition at $350 per share. 1,510,950
07/30/2021 Executive Officer Swiss
1,116   Disposition at $350 per share. 390,600
07/30/2021 Executive Officer Swiss
4,317   Disposition at $350 per share. 1,510,950
07/30/2021 Executive Officer Swiss
1,116   Disposition at $350 per share. 390,600
06/22/2021 Executive Officer Swiss
500   Disposition at $374.8 per share. 187,400
06/22/2021 Executive Officer Swiss
500   Disposition at $374.8 per share. 187,400
06/17/2021 Executive Officer Swiss
3,000   Disposition at $348.6 per share. 1,045,800
06/17/2021 Executive Officer Swiss
2,000   Disposition at $373.13 per share. 746,250
06/17/2021 Executive Officer Swiss
3,000   Disposition at $348.6 per share. 1,045,800
06/17/2021 Executive Officer Swiss
2,000   Disposition at $373.13 per share. 746,250
/news/latest/company/us/rhhvf

MarketWatch News on RHHVF

  1. Merck & Co. Inc. stock falls Wednesday, underperforms market

    5:10 p.m. Nov. 23, 2022

    - MarketWatch Automation

  2. Eli Lilly & Co. stock rises Wednesday, still underperforms market

    5:06 p.m. Nov. 23, 2022

    - MarketWatch Automation

  3. Amgen Inc. stock underperforms Wednesday when compared to competitors

    4:36 p.m. Nov. 23, 2022

    - MarketWatch Automation

  4. Abbott Laboratories stock rises Wednesday, outperforms market

    4:33 p.m. Nov. 23, 2022

    - MarketWatch Automation

  5. Merck & Co. Inc. stock rises Tuesday, still underperforms market

    5:09 p.m. Nov. 22, 2022

    - MarketWatch Automation

  6. Eli Lilly & Co. stock underperforms Tuesday when compared to competitors

    5:06 p.m. Nov. 22, 2022

    - MarketWatch Automation

  7. Amgen Inc. stock underperforms Tuesday when compared to competitors

    4:36 p.m. Nov. 22, 2022

    - MarketWatch Automation

  8. Abbott Laboratories stock rises Tuesday, still underperforms market

    4:33 p.m. Nov. 22, 2022

    - MarketWatch Automation

  9. Merck & Co. Inc. stock outperforms competitors on strong trading day

    5:09 p.m. Nov. 21, 2022

    - MarketWatch Automation

  10. Eli Lilly & Co. stock falls Monday, still outperforms market

    5:06 p.m. Nov. 21, 2022

    - MarketWatch Automation

  12. Abbott Laboratories stock outperforms market on strong trading day

    4:33 p.m. Nov. 21, 2022

    - MarketWatch Automation

  13. Merck & Co. Inc. stock rises Friday, outperforms market

    5:09 p.m. Nov. 18, 2022

    - MarketWatch Automation

  14. Eli Lilly & Co. stock rises Friday, still underperforms market

    5:06 p.m. Nov. 18, 2022

    - MarketWatch Automation

  15. Amgen Inc. stock falls Friday, underperforms market

    4:36 p.m. Nov. 18, 2022

    - MarketWatch Automation

  16. Abbott Laboratories stock outperforms competitors on strong trading day

    4:33 p.m. Nov. 18, 2022

    - MarketWatch Automation

  17. Merck & Co. Inc. stock outperforms market on strong trading day

    5:09 p.m. Nov. 17, 2022

    - MarketWatch Automation

  18. Eli Lilly & Co. stock outperforms competitors on strong trading day

    5:06 p.m. Nov. 17, 2022

    - MarketWatch Automation

  19. Amgen Inc. stock rises Thursday, outperforms market

    4:36 p.m. Nov. 17, 2022

    - MarketWatch Automation

  21. Loading more headlines...
/news/nonmarketwatch/company/us/rhhvf

Other News on RHHVF

  1. IDNA: Healthcare Dashboard For November

    12:26 p.m. Nov. 16, 2022

    - Seeking Alpha

  2. Kodiak: Turnaround Strategy Has Shown Life Thus Far

    1:17 p.m. Nov. 14, 2022

    - Seeking Alpha

  3. Aurinia: A Commercial Stage Company With Major Headwinds

    4:44 a.m. Nov. 6, 2022

    - Seeking Alpha

  7. Akero: Putting Together The Pieces They Let Us See

    5:51 p.m. Oct. 25, 2022

    - Seeking Alpha

  8. An Overview Of Today's Alzheimer's Disease Development Field

    4:29 p.m. Oct. 18, 2022

    - Seeking Alpha

  9. Roche: Comment On Q3 Results

    4:00 p.m. Oct. 18, 2022

    - Seeking Alpha

  10. Guardant: Saving Lives One Blood Test At A Time

    11:31 p.m. Oct. 15, 2022

    - Seeking Alpha

  11. IXJ Has A Shot At Earnings Growth But Is Still Too Expensive

    1:55 a.m. Oct. 15, 2022

    - Seeking Alpha

  12. BioMarin Pharmaceutical: Leader In Rare Disease Innovation

    10:11 p.m. Oct. 2, 2022

    - Seeking Alpha

  13. Roche: New Drugs Will Outpace Biosimilar Competition

    10:21 a.m. Sept. 29, 2022

    - Seeking Alpha

  14. Invitae Busted Business Model Offers A Tactical Opportunity

    12:05 p.m. Sept. 23, 2022

    - Seeking Alpha

  17. TG Therapeutics: We Are Just Hanging In There

    11:51 a.m. Sept. 21, 2022

    - Seeking Alpha

  19. Teva Pharmaceutical: Investment Opportunity During Fed Rate Hike

    3:21 a.m. Sept. 18, 2022

    - Seeking Alpha

  20. Teva Pharmaceutical: Past Behind And A Promising 2023

    5:00 p.m. Sept. 16, 2022

    - Seeking Alpha

  21. Loading more headlines...

At a Glance

Roche Holding AG

Grenzacherstrasse 124

Basel, Basel-Stadt (Basle Town) 4058

Phone

41 616881111

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

01/0002

View SEC Filings

Revenue

$63.28B

Net Income

$13.53B

2022 Sales Growth

0.8%

Employees

-

Annual Report for RHHVF

/news/pressrelease/company/us/rhhvf

Press Releases on RHHVF

Link to MarketWatch's Slice.